ISOThrive Inc. is a Clinical Stage Biotech Company
Microbiome Therapeutics
Treating Chronic Disease Caused by Microbiome Dysbiosis
We develop novel, proprietary digestion-resistant carbohydrates that target specific bacteria to correct microbiome dysbiosis. Correcting dysbiosis is a potentially disease modifying MoA in numerous disease states of high unmet need.
The company’s lead asset, ISOT-101, is a Ph2 ready maltosyl-isomaltooligosaccharide (MIMO).
Assets
MIMO:
A “Keystone” microbiome carbohydrate
ISOT-101 a novel patented and patents-pending prebiotic therapeutic.
It is a proprietary digestion-resistant carbohydrate, maltosyl-isomaltooligosaccharide (MIMO), which is an energy source for targeted beneficial bacteria.
Initial indications include GERD, IBS-C and Functional Dyspepsia.
Lightning™ Rapid Carbohydrate Drug Discovery Platform
Different bacteria prefer different types of carbohydrates.
With our Lightning Rapid Carbohydrate Drug Discovery Platform, we can create a differentiated pipeline of novel MIMO’s targeting any number of GI conditions, both upper and lower GI profiles
Rosetta™ Microbiome Precision Medicine Platform
Information on the abundance of metabolic functions possessed within a given bacterial community coupled with knowledge of their microFood™ preference hierarchies enables us to algorithmically select the ideal microFood™ blend to achieve a beneficial activity shift to (a) alleviate disease or, (b), achieve more optimal health.
Pipeline
Contact Us
Looking for more information about ISOThrive? Submit your email below, and we will reach out to you!